Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 1, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Toripalimab

"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."

Trial Locations (2)

40037

RECRUITING

the second affiliated hospital of Army medical university, Chongqing

400000

RECRUITING

Xinqiao Hospital of Chongqing, Chongqing

All Listed Sponsors
collaborator

Southwest Hospital, China

OTHER

collaborator

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

collaborator

Chongqing University Cancer Hospital

OTHER

lead

Xinqiao Hospital of Chongqing

OTHER